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Abstract
Introduction: Myofibrillar myopathies are characterized by progressive muscle weakness and impressive abnormal
protein aggregation in muscle fibers. In about 10 % of patients, the disease is caused by mutations in the MYOT
gene encoding myotilin. The aim of our study was to decipher the composition of protein deposits in
myotilinopathy to get new information about aggregate pathology.
Results: Skeletal muscle samples from 15 myotilinopathy patients were included in the study. Aggregate and
control samples were collected from muscle sections by laser microdissection and subsequently analyzed by a
highly sensitive proteomic approach that enables a relative protein quantification. In total 1002 different proteins
were detected. Seventy-six proteins showed a significant over-representation in aggregate samples including 66
newly identified aggregate proteins. Z-disc-associated proteins were the most abundant aggregate components,
followed by sarcolemmal and extracellular matrix proteins, proteins involved in protein quality control and
degradation, and proteins with a function in actin dynamics or cytoskeletal transport. Forty over-represented
proteins were evaluated by immunolocalization studies. These analyses validated our mass spectrometric data and
revealed different regions of protein accumulation in abnormal muscle fibers. Comparison of data from our
proteomic analysis in myotilinopathy with findings in other myofibrillar myopathy subtypes indicates a characteristic
basic pattern of aggregate composition and resulted in identification of a highly sensitive and specific diagnostic
marker for myotilinopathy.
Conclusions: Our findings i) indicate that main protein components of aggregates belong to a network of
interacting proteins, ii) provide new insights into the complex regulation of protein degradation in myotilinopathy
that may be relevant for new treatment strategies, iii) imply a combination of a toxic gain-of-function leading to
myotilin-positive protein aggregates and a loss-of-function caused by a shift in subcellular distribution with a
deficiency of myotilin at Z-discs that impairs the integrity of myofibrils, and iv) demonstrate that proteomic analysis
can be helpful in differential diagnosis of protein aggregate myopathies.
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Introduction
Myofibrillar myopathies (MFM) comprise a genetically
and clinically heterogeneous group of inherited muscle
disorders characterized by focal disintegration of myofi-
brils predominantly at the Z-discs and by sarcoplasmic
protein aggregation in muscle fibers [1–3]. In approxi-
mately 10 % of MFM patients, the disease is caused by
mutations in the MYOT (synonym TTID) gene on
chromosome 5q31 [4, 5]. This gene encodes the 57 kDa
Z-disc protein myotilin [6], an actin-cross-linking protein
that plays an important role in sarcomere assembly and
stabilization of myofibrillar Z-discs [6, 7]. Myotilin con-
sists of a unique serine-rich amino terminal region, two
Ig-like domains necessary for the formation of antiparallel
myotilin dimers, and a short carboxy terminal tail [6, 7]. It
directly binds filamin C [8], α-actinin [6, 7], FATZ-1 [9]
and ZASP [10].
MFM associated with myotilin mutations, hereafter re-
ferred to as myotilinopathy, usually manifests between the
5th and 8th decade of life with progressive muscle weak-
ness most often starting at distal lower limbs [4, 5, 11].
Peripheral neuropathy, cardiomyopathy and respiratory
failure have been described in a subset of patients but are
not constant features of myotilinopathy [4, 11, 12].
Histological characteristics of myotilinopathy include
variation of fiber size, fibro-fatty tissue proliferation, type I
fiber predominance, core-like lesions, rimmed vacuoles and
non-rimmed vacuolated areas. Indeed, the most prominent
myopathological features in modified trichrome stain are
pleomorphic protein deposits in so-called abnormal fibers
described as hyaline dense inclusions, non-hyaline amorph-
ous inclusions, spheroid inclusion bodies or nemaline-like
bodies [11, 13]. Immunohistochemical studies identified an
accumulation of several proteins in these deposits, includ-
ing myotilin and other Z-disc proteins, ectopically
expressed sarcolemmal proteins and proteins involved in
protein degradation pathways [4, 5, 11, 14–16]. However,
since these immunolocalization studies were hypothesis-
driven and restricted to pre-selected proteins, the precise
constitution of deposits and the mechanisms of protein
aggregation are largely unknown.
We established a highly sensitive proteomic ap-
proach to decipher the composition of MFM aggre-
gates selectively collected from abnormal fibers by
laser microdissection [17, 18]. We already applied this
method in filaminopathy and desminopathy [17, 18], two
MFM subtypes caused by mutations in FLNC and DES,
respectively. Analysis of samples from six filaminopathy
[17] and five desminopathy [18] patients revealed several
novel aggregate components and provided new insights
into the pathomechanisms of these diseases. In addition,
subtype specific proteomic profiles were detected that can
be helpful in differential diagnosis of protein aggregate
myopathies.
We here present a proteomic study in myotilinopathy,
including samples from 15 patients harboring four differ-
ent MYOT mutations. We used our established combined
laser microdissection and mass spectrometry approach to
identify new disease-relevant proteins that accumulate in
abnormal fibers. Extensive immunofluorescence studies
were performed to validate our proteomic findings and to
get a deeper insight into the subcellular distribution of
proteins. Furthermore, we compared the results with
our previous findings in filaminopathy and desminopathy




Skeletal muscle samples from 15 myotilinopathy patients
with a histological phenotype typical of MFM and with
known pathogenic mutations in exon 2 of MYOT were in-
cluded in this study. Two patients carried a p.Lys36Glu
mutation [11], one patient a p.Ser55Phe mutation [4, 11],
six patients a p.Ser60Cys mutation [4, 11], and six patients
a p.Ser60Phe mutation [4, 11]. More detailed data of
patients and muscle samples are presented in Table 1.
Proteomic analysis
A combined laser microdissection and label free mass spec-
trometry approach (see workflow in Fig. 1) was applied as
described by us before [17, 18] with modifications.
Laser Microdissection and sample processing
Frozen sections (10 μm) of skeletal muscle samples
(see above) were used for sample collection by laser
microdissection. Immunofluorescence staining with a
Table 1 Overview of myotilinopathy patients included in this study
ID Gender Age at biopsy [years] Muscle MYOT mutation
1 Male 78 biceps brachii p.Ser60Phe
2 Female 64 gastrocnemius p.Ser60Cys
3 Female 74 vastus lateralis p.Ser55Phe
4 Female 82 tibialis anterior p.Ser60Phe
5 Male 80 vastus lateralis p.Lys36Glu
6 Female 81 vastus lateralis p.Lys36Glu
7 Male 78 biceps brachii p.Ser60Phe
8 Male 52 vastus lateralis p.Ser60Cys
9 Male 72 gastrocnemicus p.Ser60Cys
10 Male 77 tibialis anterior p.Ser60Cys
11 Female 85 vastus lateralis p.Ser60Cys
12 Male 65 vastus lateralis p.Ser60Phe
13 Female 69 deltoideus p.Ser60Cys
14 Male 71 tibialis anterior p.Ser60Phe
15 Male 80 vastus lateralis p.Ser60Phe
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primary antibody directed against myotilin (Additional
file 1: Table S1) to detect protein aggregation in abnor-
mal muscle fibers was performed as described [18]. A
total area of 250,000 μm2 of protein aggregates and sur-
rounding sarcoplasm (hereinafter referred as “aggregate
samples”) and the same area of sarcoplasm of aggregate-
free muscle fibers from the same sections (intraindividual
“control samples”) were collected into tubes with 40 μl
formic acid (FA, 98–100 %) by laser microdissection
(LMD 6500, Leica Microsystems, Wetzlar, Germany).
After incubation for 30 min at room temperature and
sonification (35 kHz) for 5 min (RK31, BANDELIN
electronic, Berlin, Germany) the samples were centrifuged
for 10 min (12,000 g, 4 °C) and frozen at −80 °C.
Fig. 1 Workflow of our combined laser microdissection and label-free proteomic approach. Frozen skeletal muscle sections from myotilinopathy patients
were immunostained using a primary antibody directed against myotilin in order to detect protein aggregation in affected muscle fibers.
Protein aggregates (“aggregate samples”) and aggregate-free areas in fibers with a normal appearance (“control samples”) were collected
from the same section by laser microdissection (LMD). After tryptic in-solution digestion of extracted proteins, protein identification was performed by
LC-ESI-MS/MS-analysis. Proteins with an over-representation in aggregate samples compared to control samples were identified by label-free relative
quantification (spectral index calculation). For validation of proteomic data, serial cryosections of muscle samples from myotilinopathy patients were
immunostained with primary antibodies directed against selected proteins identified as over-represented in aggregate samples
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Table 2 Proteins identified as over-represented in aggregate samples in myotilinopathy
Mean proportion [‰]a
Protein Aggregates Control Ratio p value
Desmin 52.09 14.36 3.6 6.75 × 10−6
Filamin C 31.82 17.86 1.8 6.69x10−6
Myotilin 24.05 4.51 5.3 2.91 × 10−8
Xin actin-binding repeat-containing protein 2 (XIRP2) 21.75 0.10 214.8 7.66 × 10−6
Nebulin-related-anchoring protein (N-RAP) 18.19 0.57 31.7 7.31 × 10−7
Plectin 14.27 6.75 2.1 0.0003
Collagen alpha-3(VI) chain 11.22 1.99 5.6 1.88 × 10−5
Obscurin 8.49 4.68 1.8 0.0020
Xin actin-binding repeat-containing protein 1 (Xin) 7.17 0.67 10.7 1.88 × 10−7
Alpha-crystallin B chain (αB-crystallin) 6.50 1.08 6.0 1.03 × 10−5
Nestin 5.14 0.11 47.3 7.62 × 10−6
Myosin-3 4.16 1.13 3.7 0.0043
Histone H4 3.87 1.23 3.1 3.08 × 10−5
Collagen alpha-1(VI) chain 3.73 0.80 4.7 0.0005
Myosin-binding protein H (MYBPH) 3.19 0.51 6.3 0.0029
Fibrillin-1 2.90 0.58 5.0 0.0230
Dysferlin 2.71 0.33 8.2 2.91 × 10−6
Prelamin-A/C 2.67 0.56 4.8 2.44 × 10−5
PDZ and LIM domain protein 3 2.56 1.26 2.0 0.0029
Collagen alpha-2(VI) chain 2.41 0.52 4.6 0.0004
Heat shock cognate 71 kDa protein (HSPA8/Hsc70) 2.40 0.99 2.4 0.0001
Collagen alpha-1(I) chain 2.05 0.53 3.8 0.0475
Sequestosome-1 (p62) 1.75 0.03 52.0 0.0001
Collagen alpha-2(I) chain 1.62 0.58 2.8 0.0080
Tubulin alpha-4A chain 1.51 0.79 1.9 0.0074
Heat shock protein beta-1 (HSPB1/Hsp27) 1.40 0.44 3.2 0.0173
Basement membrane-specific heparan sulfate proteoglycan core protein (Perlecan) 1.25 0.26 4.8 0.0077
Laminin subunit gamma-1 1.25 0.06 20.6 0.0001
NADH-cytochrome b5 reductase 1 1.13 0.69 1.6 0.0385
Laminin subunit beta-2 1.07 0.23 4.6 0.0110
Kelch-like protein 40 1.07 0.49 2.2 0.0207
Dystrophin 1.04 0.12 8.6 0.0004
Collagen alpha-2(IV) chain 0.97 0.31 3.1 0.0016
Heat shock 70 kDa protein 1A/1B 0.90 0.42 2.2 0.0030
ATP synthase F(0) complex subunit B1, mitochondrial 0.90 0.48 1.9 0.0121
Tubulin beta chain 0.79 0.29 2.8 0.0016
Decorin 0.79 0.08 9.7 0.0230
BAG family molecular chaperone regulator 3 (BAG3) 0.71 0.14 5.2 0.0007
Collagen alpha-1(III) chain 0.69 0.19 3.6 0.0348
Microsomal glutathione S-transferase 3 (MGST3) 0.68 0.27 2.5 0.0365
Synaptophysin-like protein 2 0.57 0.19 2.9 0.0087
Myosin-14 0.52 n.d. n.a. 0.0203
Muscle-related coiled-coil protein (MURC) 0.49 n.d. n.a. 0.0491
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Subsequently, a tryptic in solution-digestion was per-
formed as described [18].
Mass spectrometry and relative protein quantification
The samples were analyzed by nanoHPLC-ESI-MS/MS-
analysis. Nano-HPLC was performed on an UltiMate 3000
RSLC nano LC system (Thermo Fisher Scientific,
Dreieich, Germany). Samples were loaded on a trap col-
umn (Acclaim®PepMap 100, 100 μm× 2 cm, C18, particle
size 5 μm, pore size 100 Å) with 0.1 % TFA (flow rate
10 μl/min). After sample concentration and a washing
step the trap column was serially connected with an ana-
lytical column (Acclaim®PepMap RSLC, 75 μm x 50 cm,
C18, particle size 2 μm, pore size 100 Å), and peptides
were separated with a flow rate of 400 nl/min by using a
solvent gradient from 4 % A to 40 % B (A: 0.1 % FA, B:
84 % acetonitrile, 0.1 % FA) for 95 min. The HPLC system
was directly coupled to a nanoelectrospray ionization
source of a LTQ Orbitrap Elite mass spectrometer (Thermo
Fisher Scientific, Dreieich, Germany). Ionization was per-
formed using a nanoelectrospray source with a spray volt-
age of 1500 V and capillary temperature of 275 °C. The
Table 2 Proteins identified as over-represented in aggregate samples in myotilinopathy (Continued)
NADH-cytochrome b5 reductase 3 0.45 0.07 6.8 0.0010
Myopalladin 0.44 n.d. n.a. 0.0027
Microtubule-associated protein 4 (MAP4) 0.43 0.02 25.9 0.0110
Sarcolemmal membrane-associated protein 0.40 0.10 4.0 0.0131
Protein kinase C and casein kinase substrate in neurons protein 3 (PACSIN 3) 0.40 0.02 20.2 0.0041
Next to BRCA1 gene 1 protein (NBR1) 0.37 n.d. n.a. 0.0057
Supervillin 0.31 0.09 3.3 0.0315
14-3-3 protein gamma 0.30 0.08 3.8 0.0134
Tropomodulin-1 0.29 0.02 15.0 0.0019
Syncoilin 0.28 n.d. n.a. 0.0021
Voltage-dependent calcium channel subunit alpha-2/delta-1 0.28 0.02 16.7 0.0084
Histone H1.0 0.26 n.d. n.a. 0.0016
Signal recognition particle subunit SRP68 0.26 0.04 6.0 0.0258
Unconventional myosin-XVIIIa 0.26 n.d. n.a. 0.0043
Tubulin beta-4B chain 0.24 0.04 5.8 0.0013
Xaa-Pro aminopeptidase 1 0.23 n.d. n.a. 0.0018
Myeloid leukemia factor 2 0.22 n.d. n.a. 0.0021
Myosin-10 0.17 n.d. n.a. 0.0455
Elastin 0.16 n.d. n.a. 0.0465
Protein NipSnap homolog 2 0.16 n.d. n.a. 0.0254
60S ribosomal protein L12 0.16 0.03 6.3 0.0355
Heat shock protein beta-8 (HSPB8/Hsp22) 0.15 n.d. n.a. 0.0053
Epoxide hydrolase 1 0.15 n.d. n.a. 0.0461
Y-box-binding protein 3 (YBX3) 0.12 n.d. n.a. 0.0141
60S ribosomal protein L22 0.12 n.d. n.a. 0.0490
60S ribosomal protein L7 0.10 n.d. n.a. 0.0330
Collagen alpha-3(IV) chain 0.09 n.d. n.a. 0.0337
CD59 glycoprotein 0.09 n.d. n.a. 0.0333
SET-binding protein 0.09 n.d. n.a. 0.0333
78 kDa glucose-regulated protein (GRP78/BiP) 0.29 0.05 5.7 0.0526*
Cysteine and glycine-rich protein 3 (CSRP3) 0.21 0.08 2.8 0.0504*
Delta-sarcoglycan 0.07 n.d. n.a. 0.0781*
Thrombospondin-4 0.07 n.d. n.a. 0.0727*
n.d. not detected, n.a. not applicable. Protein names marked in bold letters: proteins included in immunolocalization studies
*p value between 0.05 and 0.1 but validated by immunofluorescence studies
aper mill of total spectral counts
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Fig. 2 Functional classification and interactions of proteins identified as over-represented in myotilinopathy aggregates samples. a Results of
proteomic analysis in myotilinopathy. Proteins identified as over-represented in aggregate samples by mass spectrometric analysis are grouped
with regard to their localization or main function. Shown are proportions in aggregate and control samples. Z-disc (−associated) proteins constituted
the most abundant group of over-represented proteins, followed by proteins of the sarcolemma and extracellular matrix (ECM), proteins involved in
protein quality control and degradation and proteins with a function in actin dynamics or cytoskeletal transport. b Schematic illustration of
over-represented proteins which were verified by immunofluorescence studies and of protein-protein interactions. Each protein is termed by
the name of its encoding gene (see Additional file 2: Table S2). Direct protein interactions, identified by review of the literature, are depicted by
solid connecting lines. Indirect protein interactions are depicted by a dashed connecting line
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mass spectrometer was operated in a data dependent
acquisition. Full MS spectra were scanned between 300
and 2000 m/z (resolution 60,000, AGC 1 × 106) to de-
tect precursor ions. Lock mass polydimethylcyclosilox-
ane (m/z 445.120) was used for internal calibration.
The m/z values initiating MS/MS were set on a dynamic
exclusion list for 35 s and the 20 most intensive ions
(charge >1) were selected for MS/MS-fragmentation.
Fragments were generated by low-energy collision-
induced dissociation with normalized collision energy of
Fig. 3 Individual myotilin/filamin C ratios in aggregate samples from myotilinopathy, desminopathy and filaminopathy patients. Proportions of
myotilin and filamin C in aggregate samples were determined by our proteomic approach. The myotilin/filamin C ratio was always above 0.3 in
samples from 15 myotilinopathy patients and below 0.3 in all filaminopathy cases (n = 6) and in 4 out of 5 desminopathy patients
Fig. 4 Abnormal areas in skeletal muscle fibers with protein aggregates in myotilinopathy. Serial skeletal muscle cryosections from a myotilinopathy
patient (ID1 in Table 1) were stained with modified Gomori trichrome and double-immunostained with primary antibodies directed against myotilin
and filamin C. DAPI was used to visualize nuclei. Three different areas of protein accumulation were detected in abnormal fibers: Abnormal areas A1 appear
hyaline on trichrome stain and are characterized by aggregation of myotilin and several other proteins (see Table 3) including filamin C. Abnormal areas A2
are located in the sarcoplasm of abnormal fibers, appear dark blue in trichrome stain and are characterized by a decreased immunoreactivity for myotilin
and a strong accumulation of filamin C (among other proteins, see Table 3). Abnormal areas 3 are located around subsarcolemmal vacuoles in abnormal
fibers, appear hyaline-purple in trichrome stain and show a decreased immunoreactivity for myotilin and an increased immunoreactivity for filamin C
(and other proteins, see Table 3). Scale bar = 20 μm
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35 % (isolation width 2, activation time 10 ms). After ESI-
MS/MS analysis mass spectrometric data were searched
against a human protein database containing the entire
Uniprot/Swissprot (release 2014/10, 546,790 entries) using
Mascot search engine (Matrixscience, London, UK) with
the following search parameters: peptide mass tolerance
10 ppm, fragment mass tolerance 0.5 Da, one missed
cleavage and carbamidomethylation (C), oxidation (M),
phosphorylation (S, T, Y) as variable modifications. The
quality of identified peptide spectrum matches was evalu-
ated by calculating a FDR threshold of 1 % using the
in-house developed software “PIA-Protein Inference
Algorithm” [19] (http://mpc-bioinformatics.github.io/pia/).
Only peptides that were unique within the complete data
set were considered for final analysis to prevent an as-
signment to different proteins due to sequence homolo-
gies. Protein quantification was performed by summing
up all peptide spectrum matches (hereinafter referred as
“spectral counts”) belonging to the respective protein
followed by a normalization step. For normalization the
proportion (in ‰) of spectral counts for each protein
based on total sum of spectral counts in the individual
samples was calculated. To identify proteins that were
over-represented in aggregate samples, the ratios be-
tween the averaged proportions in aggregate and con-
trol samples were calculated and a two-tailed unpaired
Fig. 5 Immunolocalization of Z-disc (−associated) proteins I. Serial skeletal muscle cryosections from a myotilinopathy patient (ID1 in Table 1)
were double-stained with antibodies recognizing the indicated Z-disc (−associated) proteins and either filamin C or myotilin as a positive control to
localize abnormal fibers. Nuclei were visualized by DAPI staining. Results of semiquantitative evaluation of signal intensities in the different abnormal
areas A1–A3 are specified in Table 3. A1: abnormal area 1; A2: abnormal area 2; A3: abnormal area 3. Scale bar = 50 μm
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t-test (equal variances assumed) was conducted for each
protein. A protein was considered as significantly over-
represented when the aggregate to control ratio was
>1.5 and the p-value <0.05. In addition, we compared
the results of proteomic analysis in myotilinopathy pa-
tients with data from our previous studies in filamino-
pathy and desminopathy [17, 18] using the same
modified parameters described above. For identification
of diagnostic markers for myotilinopathy, proteomic
data from 10 myotilinopathy patients (ID 1–10) were
evaluated for differences in ratios and proportions of
proteins compared to findings in filaminopathy and
desminopathy. Potential markers were subsequently
checked in the remaining 5 myotilinopathy patients (ID
11–15) in a prospective manner. Specificity and sensi-
tivity were calculated using 2 × 2 contingency tables.
Validation of proteomic data by immunolocalization
studies
We used double immunofluorescence staining to assess the
localization of selected proteins that were identified as
over-represented in aggregate samples by our proteomic
analysis. 5-μm-thick serial frozen skeletal muscle sections
from three myotilinopathy patients (IDs 1, 10 and 11) were
incubated overnight at 4 °C with primary antibodies
directed against 40 different proteins (Additional file 1:
Table S1). Myotilin or filamin C immunostaining was used
to identify abnormal fibers with protein deposits. After
Fig. 6 Immunolocalization of Z-disc (−associated) proteins II. Double immunofluorescence staining was performed on serial skeletal muscle cryosections
from a myotilinopathy patient (ID1 in Table 1) using antibodies directed against myopalladin, desmin, plectin, nestin, and syncoilin and either filamin C or
myotilin. Nuclei were visualized by the blue-fluorescent DAPI nucleic acid stain. Data of semiquantitative assessment of immunofluorescence intensities in
abnormal areas A1–A3 are listed in Table 3. Scale bar = 50 μm
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three washing steps with PBS for 5 min the sections were
incubated with isotype specific secondary antibodies conju-
gated with DyLight 488 (Dianova, Hamburg, Germany; di-
lution 1:1000) or Texas Red (Jackson Immuno Research,
West Grove, Pennsylvania, USA; dilution 1:500) for 45 min
at RT, followed by three washing steps with PBS for 5 min.
Nuclei were displayed by incubation with 4’, 6-diamidino-2-
phenylindole (DAPI) (Roche Diagnostics, Indianapolis, IN,
USA; dilution 1:10,000) for 1 min at 37 °C. The staining
procedure was finished by two washing steps with PBS for
5 min. Stained sections were mounted in Roti®-Mount
FluorCare (Carl Roth, Karlsruhe, Germany) and analyzed
using an IX83 inverted microscope system (Olympus,
Hamburg, Germany).
Results
Proteomic analysis in myotilinopathy
Mass spectrometric analysis of aggregate and control sam-
ples identified 1002 different proteins. 72 of these proteins
showed a statistically significant over-representation in ag-
gregate samples with a ratio >1.5 compared to control
samples (Table 2, for UniProtKB/Swiss-Prot accession
numbers and gene names see Additional file 2: Table S2).
Although the last four proteins in Table 2 were detected as
over-represented in aggregate areas with their individual p
values (between 0.05 and 0.08) slightly below the level of
statistical significance, these proteins were also evaluated by
immunofluorescence studies. The results confirmed an ac-
cumulation in abnormal muscle fibers (see below).
Fig. 7 Immunolocalization of proteins involved in chaperone-assisted selective autophagy (CASA) and NBR1-mediated selective autophagy. Serial
skeletal muscle cryosections from a myotilinopathy patient (ID1 in Table 1) were double-stained with antibodies recognizing the indicated CASA
components (BAG3, HSPB8/Hsp22, HSPA8/Hsc70, p62) and NBR1 and either filamin C or myotilin. Nuclei were visualized by DAPI staining. Results
of semiquantitative evaluation of signal intensities in the different abnormal areas A1–A3 are specified in Table 3. Scale bar = 50 μm
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A functional classification of proteins by review of the lit-
erature revealed that Z-disc and Z-disc-associated proteins,
including the disease causing protein myotilin, were most
abundantly over-represented in aggregate samples, followed
by sarcolemmal and extracellular matrix proteins, proteins
involved in protein quality control and degradation, and
proteins with a function in actin dynamics or cytoskeletal
transport (Fig. 2). Proteomic profiles of aggregates collected
from different muscles were largely homogeneous and
independent of the specific MYOT mutation (Additional
file 3: Figure S1).
Comparison of mass spectrometric analysis in different
MFM subtypes
The comparison of data from proteomic analysis in myoti-
linopathy, filaminopathy and desminopathy revealed that
desmin, filamin C, myotilin, N-RAP, Xin, Xirp2, αB-
crystallin, and nestin were always over-represented in ag-
gregate samples irrespective of the MFM subtype, although
differences in ratios and proportions were detected. The
ratio of the myotilin and filamin C proportions in aggre-
gate samples was identified as a new diagnostic marker for
myotilinopathy with a high sensitivity (100 %) and specifi-
city (91 %) in our MFM cohort (Fig. 3). This ratio was al-
ways above 0.3 in samples from myotilinopathy patients
(range 0.34–1.17) and below 0.3 in all filaminopathy
(range 0.07–0.1) and in 4 out of 5 desminopathy patients
(range 0.11–0.26).
Our previous proteomic studies [18] identified the filamin
C ratio (proportion in aggregate samples divided by propor-
tion in control samples) as a diagnostic marker to differen-
tiate filaminopathy from desminopathy. This ratio was
always above 6 in filaminopathy samples (range 6.6–8.6)
and below 5 in desminopathy samples (range 1.9–4.5). Our
data presented here revealed an intraindividual filamin C
ratio below 4 (range 1.1–3.9) in all 15 myotilinopathy
patients indicating that the filamin C ratio is also suited for
differentiation of filaminopathy from myotilinopathy (sensi-
tivity of this diagnostic marker to detect filaminopathy in
our MFM cohort 100 %, specificity 100 %).
Fig. 8 Immunolocalization of proteins involved in unfolded protein response (UPR), oxidative stress response and transcription regulation. Serial skeletal
muscle cryosections from a myotilinopathy patient (ID1 in Table 1) were double-stained with antibodies recognizing GRP78/BiP, thrombospondin 4
(both involved in UPR), MGST3 (related to oxidative stress response), and YBX3 (transcription regulation) and either filamin C or myotilin.
Nuclei were visualized by DAPI staining. Results of semiquantitative evaluation of signal intensities in the different abnormal areas A1–A3
are specified in Table 3. Scale bar = 50 μm
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Validation of proteomic data by immunofluorescence
studies
Our extensive immunolocalization studies confirmed
the results of proteomic analysis. Forty proteins de-
tected as over-represented in aggregate samples also
showed increased immunoreactivities in fibers harbor-
ing protein aggregates. However, the distribution pat-
tern of protein accumulation varied considerably
between individual proteins.
Myotilin localized in sarcoplasmic aggregates of variable
size and shape (Figs. 4, 5, 6, 7, 8, 9, 10 , 11 and 12). The
proportion of abnormal fibers with myotilin-positive ag-
gregates varied between <10 % and >50 % in sections of
muscle samples from different patients (Additional file 4:
Figure S2). Consistent with proteomic analysis, other pro-
teins assessed by immunofluorescence studies also showed
an accumulation in at least a part of the myotilin-positive
protein deposits (Figs.. 4, 5, 6, 7, 8, 9, 10, 11 and 12). Out-
side these areas, immunoreactivity for myotilin was usually
decreased (Additional file 5: Figure S3) in abnormal fibers,
whereas the signal intensities of other evaluated proteins
were partly (locally) increased (Figs. 4, 5, 6, 7, 8, 9, 10, 11
and 12). Based on our immunofluorescence findings, we
defined three different areas in abnormal fibers (Fig. 4):
Abnormal areas A1: areas with myotilin aggregation
(Fig. 4).
Abnormal areas A2: sarcoplasmic areas showing a de-
creased immunoreactivity for myotilin but a strong ac-
cumulation of a subset of Z-disc proteins, chaperones
and proteins involved in sarcoplasmic reticulum stress
and actin dynamics (Figs. 4, 5, 6, 7, 8, 9, 10 and 11,
Table 3).
Abnormal areas A3: areas surrounding subsarcolem-
mal vacuoles (Fig. 4) with decreased or absent myotilin
immunoreactivity, but strong accumulation of most of
the other evaluated proteins (Figs. 4, 5, 6, 7, 8, 9, 10, 11
and 12, Table 3). Intact myofibrils were not observed in
A3 areas (Additional file 6: Figure S4)
The results of our extensive comparative immunolocal-
ization studies of i) Z-disc proteins (Figs. 5 and 6), ii) pro-
teins involved in chaperone-assisted selective autophagy
(CASA) and NBR1-mediated selective autophagy (Fig. 7),
Fig. 9 Immunolocalization of proteins involved in actin dynamics. Double immunofluorescence staining was performed on serial skeletal muscle
cryosections from a myotilinopathy patient (ID1 in Table 1) by using antibodies directed against MURC, MYBPH, tropomodulin 1, and CSRP3 (a Z-disc
protein that is also involved in actin dynamics) and either filamin C or myotilin. Nuclei were visualized by the blue-fluorescent DAPI nucleic acid stain.
Data of semiquantitative assessment of immunofluorescence intensities in abnormal areas A1–A3 are listed in Table 3. Scale bar = 50 μm
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iii) other chaperones and proteins that play a role in un-
folded protein response, oxidative stress and transcription
regulation (Fig. 8 and Additional file 7: Figure S5), iv) pro-
teins involved in actin dynamics (Fig. 9) and microtubule
organization and vesicle transport (Fig. 10), and v) sarco-
lemmal proteins (Fig. 11) are depicted in the respective
figures. Immunofluorescence stainings of control muscle
fibers are displayed in Additional file 8: Figure S6. H&E
and modified Gomori trichrome stains of muscle fibers
presented in Figs. 5, 6, 7, 8, 9, 10 and 11 are shown in
Additional file 4: Figure S2. Results of semiquantitative as-
sessment of immunofluorescence signal intensities in
areas A1–A3 (compared to normally looking intraindivi-
dual control fibers) are listed in Table 3.
Extracellular matrix (ECM) proteins showed an ectopic
cytoplasmic expression only in some abnormal fibers
(Fig. 12). Collagen VI and laminin displayed a diffuse stain-
ing pattern in areas of filamin C aggregation. Collagen VI
also strongly accumulated in some areas lacking immuno-
reactivity for filamin C (Fig. 12). Perlecan and decorin im-
munoreactivity was especially increased in areas between
and around myotilin-positive aggregates (Fig. 12). 14-3-3 γ
protein showed an increased immunofluorescence signal
predominantly in angulated fibers with filamin C aggre-
gates (Additional file 9: Figure S7). Lamin A/C was located
at the nuclear lamina and its over-representation in aggre-
gate samples is obviously caused by centrally located nuclei
in aggregate areas (Additional file 7: Figure S5).
Discussion
Protein aggregation in muscle fibers is the most impres-
sive histological feature of myofibrillar myopathies and
seems to play a key role in their pathogenesis. We provide
here proteomic data of laser-microdissected sarcoplasmic
aggregates from 15 myotilinopathy patients, the largest
MFM subtype cohort that has been studied by mass spec-
trometric analysis so far. The comparison with intraindivi-
dual control samples enabled us the identification of
proteins which are over-represented in aggregates and
therefore appear to be relevant for aggregate formation or
modulation. Our innovative approach revealed essential
new information about aggregate composition in myo-
tilinopathy that pave the way for future functional
studies to investigate disease mechanisms. Further-
more, we identified a novel diagnostic biomarker that
can be helpful in differential diagnosis of protein ag-
gregate myopathies.
More than 1000 different proteins were detected by
our proteomic analysis of muscle samples from myotili-
nopathy patients and 72 of them showed a statistically
significant over-representation in aggregate samples.
Thirty-six of these 72 proteins were further evaluated by
immunofluorescence studies on muscle sections from
patients. These analyses confirmed and thus validated
our mass spectrometric results. In addition, we studied
the subcellular distribution of four additional, func-
tionally interesting proteins (GRP78/BiP, CSRP3,
Fig. 10 Immunolocalization of proteins involved in microtubule organization and vesicle transport. Serial skeletal muscle cryosections from a
myotilinopathy patient (ID1 in Table 1) were double-stained with antibodies recognizing α-Tubulin, MAP4, and PACSIN3 and either filamin C or
myotilin. Nuclei were visualized by DAPI staining. Results of semiquantitative evaluation of signal intensities in the different abnormal areas A1–A3
are specified in Table 3. Scale bar = 50 μm
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δ-sarcoglycan, thrombospondin 4), which were identified
as over-represented in aggregate samples but slightly
missed the level of statistical significance. We found
that abnormal fibers also displayed an increased immu-
noreactivity for these proteins. Only ten of the in total
76 proteins that were enriched in aggregates were previ-
ously described components of deposits in myotilinopathy,
namely myotilin [4, 11], desmin [4, 11], filamin C [13, 20],
αB-crystallin [4, 11], Xin [16], Xirp2 [16], plectin [11], dys-
trophin [4, 11], NBR1 [21] and p62 [15]. This implies that
66 aggregate proteins were newly identified. However,
considering the large number of identified proteins, false
positive results cannot be ruled out. We therefore focus our
discussion on findings that we could verify by immunolo-
calization studies.
We categorized the detected proteins by their main func-
tion and found that Z-disc-associated proteins were the
most abundant aggregate components. More than 70 % of
peptides from over-represented proteins were assigned to
this group and the proportion of these Z-disc proteins re-
lated to the total number of identified peptides was 3.7 fold
higher in aggregate samples compared to controls. Referred
to the proportion of specific over-represented proteins in
aggregate samples (see [17] for a discussion of limitations
of our proteomic approach), myotilin was one of the top
proteins. Only desmin and filamin C showed a higher pro-
portion than myotilin. Most of the other Z-disc proteins
identified as accumulated in aggregate samples are inter-
action partners of desmin or filamin C: plectin, syncoilin,
and nestin bind to desmin [22–24] and Xin, Xirp2,
obscurin, and N-RAP interact with filamin C [17, 25]. Des-
min and filamin C are indirectly connected via sarcolemmal
proteins [9, 24, 26, 27] and chaperones [17, 28–30] that also
showed an over-representation in aggregate samples (see
Fig. 2). Our results therefore indicate that protein compo-
nents of aggregates in myotilinopathy largely belong to a
network of interacting proteins. This is in accordance with
our findings in filaminopathy [17] and desminopathy [18]
and suggests that MFM aggregates are rather structured
formations than simple random depositions of aggregate-
prone proteins. The finding that Z-disc proteins are the
most abundant over-represented proteins in aggregates also
Fig. 11 Immunolocalization of sarcolemmal proteins. Double immunofluorescence staining was performed on serial skeletal muscle cryosections
from a myotilinopathy patient (ID1 in Table 1) by using antibodies directed against the sarcolemmal proteins dystrophin, dysferlin, supervillain,
and δ-sarcoglycan and either filamin C or myotilin. Nuclei were visualized by the blue-fluorescent DAPI nucleic acid stain. Data of semiquantitative
assessment of immunofluorescence intensities in abnormal areas A1–A3 are listed in Table 3. Scale bar = 50 μm
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corresponds to results of ultrastructural studies indicating
that protein aggregation in MFM primarily emanates from
Z-discs [4, 5].
The second group of aggregate components consists
of sarcolemmal and extracellular matrix proteins. An
accumulation of sarcolemmal proteins in aggregate
areas has already been described in myotilinopathy and
other MFM subtypes including filaminopathy and des-
minopathy [4, 11, 16, 31, 32]. This may be attributable
to protein-protein interactions, e.g. of dystrophin with
plectin [33] or between δ-sarcoglycan and filamin C
[27]. However, the mechanisms by which extracellular
matrix proteins are translocated to sarcoplasmic aggre-
gates remain unclear. Since some of the detected ECM
proteins (i.e. collagen VI) are not even expressed in
skeletal muscle cells [34], it is tempting to speculate
that they are translocated to the sarcoplasm via in-
creased endocytosis. Indeed, we detected an accumula-
tion of proteins in abnormal fibers which are involved
in vesicle transport and endocytosis, e.g. PACSIN 3,
but the relevance of this finding has to be further
investigated.
The third group comprises proteins involved in protein
quality control and degradation. A dysfunction of protein
degradation mediated by the ubiquitin-proteasome system
(UPS) and autophagic pathways seems to play a pivotal role
in MFM [13, 15, 35, 36]. In this context, it is an interesting
feature of all validated ECM proteins of group 2 that they
modulate autophagic signaling pathways via interactions
with specific receptors. Decorin, collagen VI and perlecan
are activators of autophagy whereas laminin acts as inhibi-
tor (see [37] for review). This demonstrates that several ag-
gregate proteins have various functions and could be
assigned to more than one group. The third group includes
further proteins with an effect on autophagic protein deg-
radation. The chaperone GRP78/BiP and thrombospon-
din 4, both detected as over-represented in aggregate
samples, are involved in endoplasmic reticulum stress
and unfolded protein response. In addition, it has
recently been shown that prolonged proteasomal
Fig. 12 Immunolocalization of extracellular matrix proteins. Serial skeletal muscle cryosections from a myotilinopathy patient (ID1 in Table 1) were
double-stained with antibodies recognizing collagen VI, laminin γ1, perlecan, and decorin and either filamin C or myotilin. Nuclei were visualized
by DAPI staining. Some abnormal fibers showed an increased immunoreactivity for collagen VI and laminin γ1 in areas of filamin C aggregation
and collagen VI also a strong accumulation in some areas with lacking immunoreactivity for filamin C. Immunoreactivities for perlecan and
decorin were predominantly increased in areas between and around myotilin-positive aggregates. Scale bar = 50 μm
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inhibition and cytosolic misfolded proteins induce an
N-terminal arginylation of GRP78/BiP [38]. Arginy-
lated GRP78/BiP (R-BiP) in turn associates with mis-
folded proteins and binds the autophagic adaptor p62.
This finally induces a selective lysosomal co-
degradation of R-BiP and p62 together with associated
cargoes including misfolded proteins [38]. A strong
immunoreactivity of myotilinopathy aggregates for p62
has already been reported [15]. Our proteomic analysis
now revealed that the proportion of p62 in aggregate
samples was 52-fold higher than in controls underlin-
ing the extreme extent of p62 enrichment in aggregate
areas. An activation of the R-BiP/p62-mediated autophagic
degradation pathway may be explained by an impairment
of the UPS in myotilinopathy, evidenced by an accumula-
tion of mutant ubiquitin in abnormal fibers [15]. p62 is
also involved in chaperone-assisted selective autophagy
(CASA), a tension-induced autophagy pathway essential
for mechanotransduction in muscle fibers [39, 40]. The
CASA complex comprises the chaperones HSPB8/
Hsp22 and HSPA8/Hsc70, and the co-chaperone
BAG3 that were also over-represented in myotilinopa-
thy aggregates. CASA facilitates degradation of dam-
aged Z-disc proteins including filamin C [39, 40]. We
therefore assume that aggregation of Z-disc proteins in
myotilinopathy induces an increased expression of
CASA components. The finding that abnormal fibers in
filaminopathy also show an increased immunoreactivity for
CASA proteins [36] suggests that this pathway may be gen-
erally important in the pathogenesis of MFM. Another ac-
cumulated protein involved in selective autophagosomal
protein degradation is NBR1, an autophagic adaptor protein
with functions similar to those of p62. Myosin binding pro-
tein H (MyBPH) seems to be involved in autophagoso-
mal membrane maturation processes [41], while the
chaperones HSPB1/Hsp27 and αB-crystallin play a role
in proteasomal protein degradation [42–44].
Taken together, our proteomic analysis identified several
proteins that seem to play a role in the complex regulation
of protein degradation in myotilinopathy. We suppose that
protein aggregation in abnormal muscle fibers induces in-
creased expression of proteins of the third group which
Table 3 Semiquantitative evaluation of signal intensities in
immunolocalization studies
Protein A1 A2 A3
Z-disc (−associated) proteins
Myotilin ↑↑↑ ↓ ↓∕-
Filamin C ↑↑∕↑↑↑ ↑↑↑ ↑↑∕↑↑↑
N-RAP ↑↑ ↑↑↑ ↑↑
XIRP2 ↑↑∕↑↑↑ ↑↑↑ ↑
Xin ↑↑∕↑↑↑ ↑↑↑ (↑)
Obscurin ↑↑ ↓ ↑↑↑
Myopalladin ↑↑∕↑↑↑ ↑↑↑ ↑∕↑↑
Desmin ↑↑↑ (↑) ↑↑↑
Plectin ↑ ↓ ↑↑↑
Nestin ↑∕↑↑ - ↑↑↑
Syncoilin ↑∕↑↑ ↑↑↑ ↑∕↑↑
Chaperone-assisted selective autophagy (CASA)/NBR1-mediated
selective autophagy
BAG3 ↑↑∕↑↑↑ - ↑↑↑
HSPB8/Hsp22 ↑↑∕ ↑↑↑ ↑↑↑ ↑↑↑
HSPA8/Hsc70 ↑↑ ↑ ↑↑↑
p62 ↑↑↑ (↑)∕↑↑ (↑)
NBR1 ↑↑∕↑↑↑ ↑ ↑↑∕↑↑↑
Further chaperones
αB-crystallin ↑∕↑↑ ↑ ↑↑↑
HSPB1/Hsp27 ↑∕↑↑ ↑↑↑ ↑↑↑
Hsp70 ↑↑ ↑ ↑↑↑
Unfolded protein response (UPR) / oxidative stress response/
transcription regulation
BiP ↑↑ ↑↑ (↑)
Thrombospondin 4 ↑↑∕↑↑↑ ↑↑↑ ↑↑
MGST3 ↑↑↑ - ↑↑↑
YBX3 ↑ ∕ ↑↑ ↑ ↑
Actin dynamics
MURC (↑)∕ ↑↑ (↑) ↑↑↑
MYBPH (↑)∕ ↑↑↑ ↑↑↑ (↑)
Tropomodulin 1 ↑↑∕ ↑↑↑ ↑↑↑ (↑)
CSRP3 ↑ ↑↑ ↑
Microtubule organization / vesicle transport
α-tubulin ↑↑ ↑ ↑↑↑
MAP4 ↑↑∕ ↑↑↑ (↑) ↑↑↑
PACSIN3 (↑)∕ ↑↑ - ↑↑↑
Table 3 Semiquantitative evaluation of signal intensities in
immunolocalization studies (Continued)
Sarcolemmal proteins
Dystrophin ↑↑ - ↑↑∕ ↑↑↑
Dysferlin ↑↑∕ ↑↑↑ ↑ ↑↑∕ ↑↑↑
Supervillin ↑ ∕ ↑↑ - ↑↑↑
δ-Sarcoglycan (↑) (↑) (↑)
A1: abnormal area 1, A2: abnormal area 2, A3: abnormal area 3;
(↑)∕↑∕↑↑∕↑↑↑: slightly/moderately/distinctly/strongly increased
immunoreactivity compared to control fibers; ↓: decreased immunoreactivity
compared to control fibers; −: no visible immunoreactivity
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interact with or support the degradation of proteins in-
volved in aggregate formation. Since these proteins are po-
tential therapeutic targets, this may be relevant for the
development of new treatment strategies. Indeed, it has
been shown that e.g. induction of chaperone expression, in-
cluding proteins that are over-represented in aggregates, ef-
ficiently prevented protein aggregation in cell and mouse
models of MFM subtypes [45–49]. However, it is unclear
if a simple over-expression of proteins involved in deg-
radation processes could be sufficient to eliminate
massive protein aggregates. In abnormal fibers impair-
ment of the UPS and autophagy, and factors like oxida-
tive stress may contribute to a resistance of aggregates
to degradation [13, 15, 32, 36, 50].
Our immunolocalization studies not only confirmed our
proteomic findings but surprisingly also revealed different
regions of protein accumulation in abnormal fibers. A1
areas correspond to myotilin-positive aggregates. These
areas were collected as aggregate samples by our laser mi-
crodissection approach and showed an accumulation of the
proteins that were identified as over-represented in
aggregate samples by mass spectrometric analysis. Abnor-
mal fibers usually displayed a decreased myotilin immuno-
reactivity outside area A1. This suggests the assumption
that there might be two different kinds of effects of MFM
causing MYOT mutations: a toxic gain-of-function leading
to myotilin-positive protein aggregates and a loss-of-
function caused by a shift in subcellular distribution with a
deficiency of myotilin at Z-discs that impairs the integrity
of myofibrils. A combination of toxic gain- and loss-of-
function has already been discussed in other protein aggre-
gation disorders, e.g. in neurodegenerative diseases [51, 52].
The loss-of-function theory in myotilinopathy is sup-
ported by identification of abnormal areas A2. These re-
gions showed a decreased myotilin signal but strong
accumulation of proteins involved in myofibrillar
stabilization, remodeling and repair, such as (co-)chaper-
ones [39, 40, 53–55], proteins with a regulatory role in actin
dynamics [41, 56–58], and the Z-disc-associated proteins
filamin C, N-RAP, Xin and Xirp2 [25, 54, 59–64]. This may
be an attempt of abnormal fibers to protect and repair
myofibrils that are disturbed due to local myotilin defi-
ciency. In addition, a lack of further proteins may also be
relevant as we detected a decreased immunoreactivity of
A2 areas for e.g. the Z-disc-associated proteins obscurin,
plectin and nestin. A separate collection and analysis of A2
areas would be a promising, but, from a technical point of
view, extremely difficult approach at the moment. A main
problem is that no specific marker for these areas has been
established so far.
A3 areas are primarily located at the periphery of abnor-
mal fibers and characterized by vacuolar changes, absence
of intact myofibrils, and increased immunoreactivity for a
plethora of proteins including desmin, plectin, nestin,
obscurin, sarcolemmal proteins, and several proteins in-
volved in proteasomal and autophagic pathways. We sup-
pose that proteins actually destined for degradation
accumulate in these areas. The formation of large vacuoles
may be a consequence of an insufficiency and impairment
of autophagy. Interestingly, the immunoreactivity for p62
was only slightly increased in A3 areas, whereas NBR1
strongly accumulated. This suggests that the relevance of
distinct selective autophagy pathways differs in A1 and A3
areas. The lack of myotilin in A3 areas indicates that it is
trapped in A1 areas. A dynamic flux of other over-
represented proteins between different aggregate areas and
surrounding sarcoplasm may be possible but this important
aspect cannot be assessed by our descriptive immunofluor-
escence studies. It would be interesting to investigate
dynamic processes by e.g. live cell imaging studies but suit-
able cell culture models of myotilinopathy have not been
established so far.
Finally, comparison of data from our proteomic
analysis in myotilinopathy with previous findings in
filaminopathy and desminopathy [17, 18] showed
striking similarities especially in respect of Z-disc-
associated proteins. Desmin, filamin C, myotilin,
Xirp2, N-RAP, Xin, αB-crystallin and nestin always
ranked among the most abundant over-represented
proteins indicating a characteristic basic pattern of
aggregate composition in MFM. Differences related
to the proportion, ratio and order of proteins
allowed the identification of subtype-specific prote-
omic profiles. The ratio of myotilin to filamin C in
aggregate samples was identified as a highly sensitive
and specific marker for myotilinopathy. In addition,
the ratio of filamin C proportions in aggregate and
control samples, previously presented as marker to
differentiate filaminopathy from desminopathy [18],
is also suitable to discern filaminopathy from myoti-
linopathy. This again demonstrates that proteomic
analysis is a valuable tool in the differential diagnosis
of MFM. Future studies in other MFM subtypes and
further protein aggregate myopathies have to address
the issue if other disease entities also display distinct
patterns of diagnostic markers.
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Conclusions
Our previous work showed that the combination of laser
microdissection with proteomic analysis is a highly sen-
sitive method to decipher the composition of protein
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aggregates in MFM. Our findings in myotilinopathy pre-
sented in this work indicate that Z-disc-associated pro-
teins, especially filamin C, desmin and their binding
partners, are the most abundant components of the
pathological aggregates in muscle fibers of myotilinopa-
thy patients. The network of interactions between sev-
eral of the accumulated proteins suggests that
sarcoplasmic aggregates are structured formations. New
information concerning over-represented chaperones
and proteins involved in the UPS and autophagic path-
ways are important for understanding pathophysiological
aspects and may be relevant for the development of
treatment strategies. Our extensive immunolocalization
studies not only confirmed the results of our proteomic
analysis but also identified different regions of protein
accumulation and a lack of myotilin outside the aggre-
gates in abnormal muscle fibers. This raised the import-
ant question whether a combination of toxic gain-of-
function and loss-of-function of myotilin is present in
myotilinopathy. The identification of the ratio of myoti-
lin to filamin C in aggregates as a highly sensitive and
specific diagnostic marker for myotilinopathy underlines
that proteomic analysis can be useful in differential diag-
nosis of myofibrillar myopathies.
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